pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma
Open Access
- 3 January 2025
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (1) , 307-321
Abstract
The blood-brain barrier (BBB) remains a major obstacle for effective delivery of therapeutics to treat central nervous system (CNS) disorders. Although transferrin receptor (TfR)-mediated transcytosis is widely employed for brain drug delivery, the inefficient release of therapeutic payload hinders their efficacy from crossing the BBB. Here, we developed a pH-responsive anti-polyethylene glycol (PEG) × anti-TfR bispecific antibody (pH-PEG engagerTfR) that can complex with PEGylated nanomedicine at physiological pH to trigger TfR-mediated transcytosis in the brain microvascular endothelial cells, while rapidly dissociating from PEGylated nanomedicine at acidic endosomes for efficient release of PEGylated nanomedicine to cross the BBB. The pH-PEG engagerTfR significantly increased the accumulation of PEGylated nanomedicine in the mouse brain compared to wild-type PEG engagerTfR (WT-PEG engagerTfR). pH-PEG engagerTfR-decorated PEGylated liposomal doxorubicin exhibited an enhanced antitumor effect and extended survival in a human glioblastoma (GBM) orthotopic xenograft mice model. Conditional release of PEGylated nanomedicine during BBB-related receptor-mediated transcytosis by pH-PEG engagerTfR is promising for enhanced brain drug delivery to treat CNS disorders.Keywords
Funding Information
- Kaohsiung Medical University (NYCUKMU-114-I005)
- National Science and Technology Council (112-2628-B-A49-010-MY3, 112-2636-B-A49-003)
- Ministry of Education, Taiwan
This publication has 68 references indexed in Scilit:
- Translational Approaches for Brain Delivery of Biologics via Cerebrospinal FluidClinical Pharmacology & Therapeutics, 2022
- Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomesActa Biomaterialia, 2020
- Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human PrimatesThe American Journal of Human Genetics, 2019
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialJournal of Inherited Metabolic Disease, 2019
- Convection-Enhanced DeliveryNeurotherapeutics, 2017
- Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rateCancer Chemotherapy and Pharmacology, 2013
- Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfallsJournal of Neuro-Oncology, 2011
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdvanced Drug Delivery Reviews, 2011
- Particle Size, Surface Coating, and PEGylation Influence the Biodistribution of Quantum Dots in Living MiceSmall, 2009
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989